Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb 28;16(8):1008-13.
doi: 10.3748/wjg.v16.i8.1008.

Preparation, physicochemical characterization and cytotoxicity in vitro of gemcitabine-loaded PEG-PDLLA nanovesicles

Lin Jia  1 , Jian-Jun Zheng, Shu-Man Jiang, Kai-Hong Huang
Affiliations

Preparation, physicochemical characterization and cytotoxicity in vitro of gemcitabine-loaded PEG-PDLLA nanovesicles

Lin Jia et al. World J Gastroenterol. .

Abstract

Aim: To investigate the preparation, physicochemical characterization and cytotoxicity in vitro of Gemcitabine-loaded poly(ethylene glycol)-block-poly(D,L-lactide) (PEG-PDLLA) nanovesicles.

Methods: The nanovesicle carriers were prepared from the amphiphilic block copolymer of PEG-PDLLA by a double emulsion technique, and gemcitabine was used as the model drug. The morphology of the nanovesicles was determined by scanning and transmission electron microscopy, and the drug content, drug entrapment and drug-release curve in vitro were detected by UV-Vis-NIR spectrophotometry. Cytotoxicity in the human pancreatic cancer cell line SW1990 was tested by 3-(4,5-dimethyl) ethiazole (MTT) assay.

Results: The gemcitabine-loaded nanovesicles were hollow nanospheres with a mean size of 200.6 nm, drug loading of 4.14% and drug embedding ratio of 20.54%. The nanovesicles showed excellent controlled release that was characterized by a fast initial release during the first 72 h, followed by a slower and continuous release. The MTT assay demonstrated that gemcitabine-loaded nanovesicles exhibited dose-dependent and time-delayed cytotoxicity in the human pancreatic cancer cell line SW1990.

Conclusion: Gemcitabine-loaded PEG-PDLLA nanovesicles prepared by a double emulsion technique exhibited good performance for controlled drug release, and had similar cytotoxic activity to free gemcitabine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Scanning electronic microphotographs of poly (ethylene glycol)-block-poly (D,L-lactide) (PEG-PDLLA) nanovesicles. A: × 40 000; B: × 20 000.
Figure 2
Figure 2
Transmission electron micrographs of PEG-PDLLA nanovesicles.
Figure 3
Figure 3
Release of gemcitabine from nanovesicles at pH 7.4 and 5.0. Data are presented as mean ± SD. P < 0.05 at every point of pH 5.0 vs pH 7.4.
Figure 4
Figure 4
IC50 of gemcitabine-loaded nanovesicles and free gemcitabine in human SW1990 pancreatic cancer cells. Data are presented as mean ± SD. aP < 0.05, cP > 0.05 vs free gemcitabine group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jia L, Zhang MH, Yuan SZ, Huang WG. Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice. World J Gastroenterol. 2005;11:447–450. - PMC - PubMed
    1. Kamath A, Yoo D, Stuart OA, Bijelic L, Sugarbaker PH. Rationale for an intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer. Recent Pat Anticancer Drug Discov. 2009;4:174–179. - PubMed
    1. Danesi R, Altavilla G, Giovannetti E, Rosell R. Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. Pharmacogenomics. 2009;10:69–80. - PubMed
    1. Reddy LH, Dubernet C, Mouelhi SL, Marque PE, Desmaele D, Couvreur P. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J Control Release. 2007;124:20–27. - PubMed
    1. Chen C, Lv G, Pan C, Song M, Wu C, Guo D, Wang X, Chen B, Gu Z. Poly(lactic acid) (PLA) based nanocomposites--a novel way of drug-releasing. Biomed Mater. 2007;2:L1–L4. - PubMed

Publication types

MeSH terms